Symmetry Partners LLC Decreases Stake in IQVIA Holdings Inc. (NYSE:IQV)

Symmetry Partners LLC trimmed its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 12.2% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,147 shares of the medical research company’s stock after selling 298 shares during the quarter. Symmetry Partners LLC’s holdings in IQVIA were worth $454,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Lazard Asset Management LLC boosted its stake in shares of IQVIA by 0.9% during the 1st quarter. Lazard Asset Management LLC now owns 3,263,944 shares of the medical research company’s stock valued at $825,416,000 after buying an additional 30,014 shares during the last quarter. Canada Pension Plan Investment Board grew its holdings in IQVIA by 6.4% during the 1st quarter. Canada Pension Plan Investment Board now owns 3,191,835 shares of the medical research company’s stock worth $807,183,000 after acquiring an additional 193,304 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of IQVIA by 3.8% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,510,685 shares of the medical research company’s stock valued at $634,927,000 after purchasing an additional 92,293 shares in the last quarter. Capital Research Global Investors lifted its position in shares of IQVIA by 7.2% during the first quarter. Capital Research Global Investors now owns 2,138,802 shares of the medical research company’s stock worth $540,882,000 after purchasing an additional 143,533 shares during the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its holdings in IQVIA by 339.6% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,067,195 shares of the medical research company’s stock valued at $478,308,000 after buying an additional 1,597,003 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of research analyst reports. Evercore ISI increased their target price on IQVIA from $230.00 to $270.00 and gave the stock an “outperform” rating in a report on Tuesday, July 23rd. UBS Group lifted their price objective on shares of IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. Morgan Stanley increased their target price on shares of IQVIA from $270.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, July 23rd. The Goldman Sachs Group began coverage on shares of IQVIA in a report on Thursday, June 6th. They issued a “buy” rating and a $270.00 price target for the company. Finally, StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday. Five research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $265.67.

IQVIA Price Performance

IQVIA stock traded up $1.40 during mid-day trading on Friday, hitting $237.47. The company’s stock had a trading volume of 552,564 shares, compared to its average volume of 1,271,741. The stock has a market capitalization of $43.29 billion, a P/E ratio of 32.44, a P/E/G ratio of 2.24 and a beta of 1.49. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73. The stock’s fifty day moving average price is $222.80 and its two-hundred day moving average price is $231.09. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80.

IQVIA (NYSE:IQV) last announced its earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The company had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.79 billion. During the same period in the previous year, the firm earned $2.22 earnings per share. IQVIA’s revenue for the quarter was up 2.3% compared to the same quarter last year. Research analysts forecast that IQVIA Holdings Inc. will post 10.21 earnings per share for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.